Scrutiny Update

Key Takeaways

• SEC inquiry began August 2022 into Merit’s China subsidiary activities
• Merit cooperated fully, providing information to SEC investigators
• Quarterly filings repeatedly referenced the ongoing investigation
• SEC concluded inquiry September 2025, no enforcement recommended
• Regulatory clearance may improve Merit’s market positioning and stock outlook

Pulse Analysis

Merit Medical Systems (NASDAQ: MMSI) has built a reputation as a leading provider of disposable medical devices, ranging from vascular access tools to infusion systems. The company’s global footprint includes a significant manufacturing and sales presence in China, a market that offers both growth opportunities and heightened regulatory scrutiny. Over the past four years, U.S. regulators have intensified oversight of American firms operating in China, especially in sectors tied to health care and technology, prompting many companies to bolster compliance programs and disclose potential risks to investors.

The SEC’s Division of Enforcement launched its inquiry in August 2022, seeking voluntary production of information about Merit’s interactions with Chinese hospitals and health‑care officials. Merit’s consistent disclosures across quarterly reports highlighted the uncertainty surrounding the investigation’s scope and potential outcomes. By April 2025, the company indicated ongoing discussions with SEC staff about a possible resolution. The decisive update in the 2025 annual report—stating that the SEC concluded the inquiry without recommending enforcement—signals that Merit’s cooperation satisfied regulatory concerns. This outcome not only removes a material legal risk but also demonstrates the effectiveness of transparent reporting and proactive engagement with U.S. authorities.

The broader implication for the med‑tech industry is clear: firms with cross‑border operations must anticipate rigorous scrutiny and be prepared to disclose material investigations promptly. Merit’s experience may serve as a benchmark for peers navigating similar regulatory landscapes, especially as geopolitical tensions continue to shape compliance expectations. With the SEC matter resolved, Merit can redirect resources toward product innovation and expansion, positioning itself to capture emerging demand in both domestic and international markets.